Iron Chelation by Deferoxamine Prevents Renal Interstitial Fibrosis in Mice with Unilateral Ureteral Obstruction
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Renal fibrosis plays an important role in the onset and progression of chronic kidney diseases (CKD). Although several mechanisms underlying renal fibrosis and candidate drugs for its treatment have been identified, the effect of iron chelator on renal fibrosis remains unclear. In the present study, we examined the effect of an iron chelator, deferoxamine (DFO), on renal fibrosis in mice with surgically induced unilateral ureter obstruction (UUO). Mice were divided into 4 groups: UUO with vehicle, UUO with DFO, sham with vehicle, and sham with DFO. One week after surgery, augmented renal tubulointerstitial fibrosis and the expression of collagen I, III, and IV increased in mice with UUO; these changes were suppressed by DFO treatment. Similarly, UUO-induced macrophage infiltration of renal interstitial tubules was reduced in UUO mice treated with DFO. UUO-induced expression of inflammatory cytokines and extracellular matrix proteins was abrogated by DFO treatment. DFO inhibited the activation of the transforming growth factor-β1 (TGF-β1)-Smad3 pathway in UUO mice. UUO-induced NADPH oxidase activity and p22(phox) expression were attenuated by DFO. In the kidneys of UUO mice, divalent metal transporter 1, ferroportin, and ferritin expression was higher and transferrin receptor expression was lower than in sham-operated mice. Increased renal iron content was observed in UUO mice, which was reduced by DFO treatment. These results suggest that iron reduction by DFO prevents renal tubulointerstitial fibrosis by regulating TGF-β-Smad signaling, oxidative stress, and inflammatory responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The authors concluded that in mice iron reduction by deferoxamine may prevent renal interstitial fibrosis by regulating TGF-beta/Smad signaling, oxidative stress, and inflammatory responses [67].”
From The utility of iron chelators in the management of inflammatory disorders (2015) · cites this paper as [67]
In the citing paper
“After a surgically induced unilateral ureter obstruction (UUO), mice treated with DFO showed significantly less fibrotic progression, less interstitial macrophage infiltration, and thereby a reduced expression of IL-1β and MCP-1 and a suppressed UUO-induced accumulation of myofibroblasts, compared with untreated mice.”
From The utility of iron chelators in the management of inflammatory disorders (2015) · cites this paper as [67]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Myofibroblasts and mechano-regulation of connective tissue remodelling
Tomasek, J. J., Gabbiani, G., Hinz, B., Chaponnier, C., & Brown, R. A. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm809 · Cited by 4,290 · cited 1×
“In addition, activated fibroblasts (also known as myofibroblasts) that express aSMA are a major source of extracellular matrix production [44].”
BackgroundThe Transforming Growth Factor-beta Family
Massague, J. (1990) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.06.110190.003121 · Cited by 3,015 · cited 1×
“Indeed, TGF-b1 is a well-known major profibrotic stimulator of collagen and extracellular matrix production in a variety of cell types [38].”
BackgroundMassagué, J. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35043051 · Cited by 1,899
Iron accumulation in Alzheimer disease is a source of redox-generated free radicals
Smith, M. A., Harris, P. L. R., Sayre, L. M., & Perry, G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.18.9866 · Cited by 1,355 · cited 1×
“[9,10], and that iron reduction therapy can ameliorate these disorders [7,8,11,12].”
BackgroundHypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition
Higgins, D. F., Kimura, K., Bernhardt, W. M., Shrimanker, N., Akai, Y., Hohenstein, B., Saito, Y., Johnson, R. S., Kretzler, M., Cohen, C. D., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30487 · Cited by 976
Ferritins: A family of molecules for iron storage, antioxidation and more
Arosio, P., Ingrassia, R., & Cavadini, P. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2008.09.004 · Cited by 886 · cited 1×
“Ferritin, an intracellular iron storage protein, reduces intracellular free iron levels, thereby suppressing catalysis of the Fenton reaction [61].”
BackgroundSato, M., Muragaki, Y., Saika, S., Roberts, A. B., & Ooshima, A. (2003) · Journal of Clinical Investigation · doi:10.1172/jci19270 · Cited by 831 · cited 2×
“Similar to its role in fibrosis, TGF-b1-Smad3 signaling is a key mediator for triggering EMT in vivo [42].”
BackgroundOberg, B. P., McMenamin, E., Lucas, F. L., McMonagle, E., Morrow, J., Ikizler, T. A. L. P., & Himmelfarb, J. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00465.x · Cited by 781 · cited 1×
“Oxidative stress is considered a contributing factor in the progression of CKD, including renal fibrosis [49].”
BackgroundWang, G., & Semenza, G. (1993) · Blood · doi:10.1182/blood.v82.12.3610.3610 · Cited by 766
Cited by
Bayır, H., Dixon, S. J., Tyurina, Y. Y., Kellum, J. A., & Kagan, V. E. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00689-x · Cited by 331
The multifaceted role of iron in renal health and disease
van Swelm, R. P. L., Wetzels, J. F. M., & Swinkels, D. W. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0197-5 · Cited by 275
Iron alters macrophage polarization status and leads to steatohepatitis and fibrogenesis
Handa, P., Thomas, S., Morgan-Stevenson, V., Maliken, B. D., Gochanour, E., Boukhar, S., Yeh, M. M., & Kowdley, K. V. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.3a0318-108r · Cited by 217
COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy
Perricone, C., Bartoloni, E., Bursi, R., Cafaro, G., Guidelli, G. M., Shoenfeld, Y., & Gerli, R. (2020) · Immunologic Research · doi:10.1007/s12026-020-09145-5 · Cited by 208
Current health risk assessment practice for dietary cadmium: Data from different countries
Satarug, S., Vesey, D. A., & Gobe, G. C. (2017) · Food and Chemical Toxicology · doi:10.1016/j.fct.2017.06.013 · Cited by 203
Wang, J., Wang, Y., Liu, Y., Cai, X., Huang, X., Fu, W., Wang, L., Qiu, L., Li, J., & Sun, L. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-00931-8 · Cited by 157
“Reportedly, DMTI was up-regulated in the kidneys of unilateral ureteral obstructioninduced CKD mice [33, 34].”
Wang, B., Yang, L., Yang, L., Liang, Y., Guo, F., Fu, P., & Ma, L. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01156-w · Cited by 153
“As reported, deferoxamine, an iron chelator, reduced the level of iron overload and the expression of proin fl ammatory cytokines and extracellular matrix proteins such as different types of collagens in UUO mice [50].”
van Raaij, S. E. G., van Swelm, R. P. L., Bouman, K., Cliteur, M. P., van den Heuvel, M. C., Pertijs, J. C. L. M., Patel, D., Bass, P., van Goor, H., Unwin, R. J., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-27107-8 · Cited by 120
van Lith, R., Gregory, E. K., Yang, J., Kibbe, M. R., & Ameer, G. A. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.06.004 · Cited by 114
The Cross‐Link between Ferroptosis and Kidney Diseases
Wang, J., Liu, Y., Wang, Y., & Sun, L. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6654887 · Cited by 115
“DFO mitigates kidney fibrosis by alleviating iron metabolism and oxidative stress in UUO mice [116].”
BackgroundSun, B., Jia, Y., Hong, J., Sun, Q., Gao, S., Hu, Y., Zhao, N., & Zhao, R. (2018) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.8b01189 · Cited by 104
Li, X., Song, J.-W., Zhang, Z.-Z., Zhang, M.-W., Liang, L., Miao, R., Liu, Y., Chen, Y., Liu, X.-Y., & Zhong, J. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.10.320 · Cited by 100
Zhang, X., & Li, X. (2022) · Metabolites · doi:10.3390/metabo12010058 · Cited by 90
“Furthermore, the inhibitory effect of iron chelators on kid ey fibrosis is als confirmed in UUO ice by alleviating iron metabolism and oxidative stress [85].”
BackgroundInfluentialQin, T., Wu, L., Hua, Q., Song, Z., Pan, Y., & Liu, T. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.112128 · Cited by 94
Xie, J., Ye, Z., Li, L., Xia, Y., Yuan, R., Ruan, Y., & Zhou, X. (2022) · Molecular Medicine Reports · doi:10.3892/mmr.2022.12772 · Cited by 71
Naito, Y., Fujii, A., Sawada, H., Oboshi, M., Iwasaku, T., Okuhara, Y., Morisawa, D., Eguchi, A., Hirotani, S., & Masuyama, T. (2015) · Hypertension Research · doi:10.1038/hr.2015.14 · Cited by 68
Modulation of iron homeostasis with hepcidin ameliorates spontaneous murine lupus nephritis
Scindia, Y. M., Wlazlo, E., Ghias, E., Cechova, S., Loi, V., Leeds, J. T., Ledesma, J., Helen, C., & Swaminathan, S. (2020) · Kidney International · doi:10.1016/j.kint.2020.01.025 · Cited by 61
Bridging translation for acute kidney injury with better preclinical modeling of human disease
Skrypnyk, N. I., Siskind, L. J., Faubel, S., & de Caestecker, M. P. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00552.2015 · Cited by 61
Iron deficiency impairs Intra-hepatic lymphocyte mediated immune response
Bonaccorsi-Riani, E., Danger, R., Lozano, J. J., Martinez-Picola, M., Kodela, E., Mas-Malavila, R., Bruguera, M., Collins, H. L., Hider, R. C., Martinez-Llordella, M., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0136106 · Cited by 57
“Thus, iron restriction has been shown to ameliorate oxidative stress and inflammatory organ damage in models of murine acute hepatitis [5, 6], experimental autoimmune encephalomyelitis (EAE) [7], renal interstitial fibrosis [8] and type 2 diabetes in rats [9].”
BackgroundRenal iron accumulation occurs in lupus nephritis and iron chelation delays the onset of albuminuria
Marks, E. S., Bonnemaison, M. L., Brusnahan, S. K., Zhang, W., Fan, W. Q., Garrison, J. C., & Boesen, E. I. (2017) · Scientific Reports · doi:10.1038/s41598-017-13029-4 · Cited by 54
Long Noncoding RNA FENDRR Exhibits Antifibrotic Activity in Pulmonary Fibrosis
Huang, C., Liang, Y., Zeng, X., Yang, X., Xu, D., Gou, X., Sathiaseelan, R., Senavirathna, L. K., Wang, P., & Liu, L. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0293oc · Cited by 57
“Iron Is Required for Fibroblast Activation Iron overload has been shown to be associated with lung, liver, and renal fibrosis (37, 39).”
BackgroundThe utility of iron chelators in the management of inflammatory disorders
Lehmann, C., Islam, S., Jarosch, S., Zhou, J., Hoskin, D., Greenshields, A., Al-Banna, N., Sharawy, N., Sczcesniak, A., Kelly, M., et al. (2015) · Mediators of Inflammation · doi:10.1155/2015/516740 · Cited by 54
“The authors concluded that in mice iron reduction by deferoxamine may prevent renal interstitial fibrosis by regulating TGF-beta/Smad signaling, oxidative stress, and inflammatory responses [67].”
BackgroundTargeting ferroptosis: a new therapeutic opportunity for kidney diseases
Long, Z., Luo, Y., Yu, M., Wang, X., Zeng, L., & Yang, K. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1435139 · Cited by 65
Ikeda, Y., Satoh, A., Horinouchi, Y., Hamano, H., Watanabe, H., Imao, M., Imanishi, M., Zamami, Y., Takechi, K., Izawa‐Ishizawa, Y., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201802724rr · Cited by 49
“Similar to skeletal muscle, iron causes tissue fibrosis in cardiovascular organs (15, 61), kidney (14, 62), and liver (63) in mouse diseasemodels.”
BackgroundSelf-citationFerroptosis in organ fibrosis: From mechanisms to therapeutic medicines
Lai, W., Wang, B., Huang, R., Zhang, C., Fu, P., & Ma, L. (2024) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2023-0137 · Cited by 56
“[55,56] The ferroptosis inhibitor Liproxstatin-1 (Lip-1) could attenuate renal fibrosis by reducing the activation of surrounding fibroblasts through inhibiting the paracrine of profibrotic factors in renal tubular epithelial cells.”
BackgroundCheng, X., Zheng, X., Song, Y., Qu, L., Tang, J., Meng, L., & Wang, Y. (2016) · Free Radical Research · doi:10.1080/10715762.2016.1181757 · Cited by 42
“found elevated NOXs activity and NOX4 expression in UUO mice [29], while Kim et al.”
BackgroundFibrosis in the central nervous system: from the meninges to the vasculature
Fehlberg, C., & Lee, J. K. (2021) · Cell and Tissue Research · doi:10.1007/s00441-021-03491-y · Cited by 39
“FDA-approved iron chelators, such as deferoxamine (Desferal), are typically used to treat iron overload syndromes, but there is accumulating evidence that it reduces fibrosis in multiple disease indications (Ikeda et al. 2014; Mohammed et al. 2016; Shen et al. 2020).”
BackgroundChen, Y., Dai, Y., Huang, Y., Zhang, L., Zhang, C., Gao, H., & Qi, Y. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02068-4 · Cited by 42
“Treatment with the iron chelator DFO can effectively reduce iron accumulation in TECs and improve the progression of renal fibrosis [11].”
Renoprotective effects of a factor Xa inhibitor: fusion of basic research and a database analysis
Horinouchi, Y., Ikeda, Y., Fukushima, K., Imanishi, M., Hamano, H., Izawa‐Ishizawa, Y., Zamami, Y., Takechi, K., Miyamoto, L., Fujino, H., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-29008-2 · Cited by 38
Self-citationvan Raaij, S. E. G., Rennings, A. J. M., Biemond, B. J., Schols, S. E. M., Wiegerinck, E. T. G., Roelofs, H. M. J., Hoorn, E. J., Walsh, S. B., Nijenhuis, T., Swinkels, D. W., et al. (2019) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00425.2018 · Cited by 47
“In chronic kidney disease animal models, tubular injury was associated with urinary iron excretion, and the reduction of circulating iron levels using a low-iron diet or treatment with an iron chelator reduced renal tubular injury (28, 29).”
BackgroundNaas, S., Schiffer, M., & Schödel, J. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00201.2023 · Cited by 49
Yasumura, S., Naito, Y., Okuno, K., Sawada, H., Asakura, M., Masuyama, T., & Ishihara, M. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.13670 · Cited by 35
Therapeutic Implications of Ferroptosis in Renal Fibrosis
Zhang, Y., Mou, Y., Zhang, J., Suo, C., Zhou, H., Gu, M. J., Wang, Z., & Tan, R. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.890766 · Cited by 45
Deferoxamine alleviates liver fibrosis induced by CC l4 in rats
Mohammed, A., Haleem, E. N. A. A., El‐Bakly, W. M., & El‐Demerdash, E. (2016) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12591 · Cited by 38
Tatsukawa, H., Otsu, R., Tani, Y., Wakita, R., & Hitomi, K. (2018) · Scientific Reports · doi:10.1038/s41598-018-25674-4 · Cited by 32
A Deep Insight into Ferroptosis in Renal Disease: Facts and Perspectives
Han, Z., Luo, Y., Chen, H., Zhang, G., You, L., Zhang, M., Lin, Y., Lan, Y., & Zhou, S. (2024) · Kidney Diseases · doi:10.1159/000538106 · Cited by 36
“In a unilateral ureteral obstruction mouse model, DFO alleviated tubulointerstitial fi brosis by modulating TGF-β -Smad signaling and oxidative stress [40].”
Ikeda, Y., Horinouchi, Y., Hamano, H., Hirayama, T., Kishi, S., Izawa‐Ishizawa, Y., Imanishi, M., Zamami, Y., Takechi, K., Miyamoto, L., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11089-0 · Cited by 31
Self-citationÇavdar, Z., Oktan, M. A., Ural, C., Çalışır, M., Koçak, A., Heybeli, C., Yıldız, S., Arıcı, A., Ellıdokuz, H., Çelik, A., et al. (2019) · Biological Trace Element Research · doi:10.1007/s12011-019-01733-3 · Cited by 30
Clioquinol Attenuates Pulmonary Fibrosis through Inactivation of Fibroblasts via Iron Chelation
Zhu, Y., Chang, J., Tan, K., Huang, S. K., Liu, X., Wang, X., Cao, M., Zhang, H., Li, S., Duan, X., et al. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0279oc · Cited by 34
Mechanisms of ferroptosis in chronic kidney disease
Zhuo, W.-Q., Wen, Y., Luo, H., Luo, Z., & Wang, L. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.975582 · Cited by 32
“Transforming growth factor β1 (TGF-β1) was shown to be a key mediator of renal fibrosis (Ikeda et al., 2014).”
BackgroundHypoxia in chronic kidney disease: towards a paradigm shift?
Faivre, A., Scholz, C. C., & de Seigneux, S. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa091 · Cited by 31
Horinouchi, Y., Murashima, Y., Yamada, Y., Yoshioka, S., Fukushima, K., Kure, T., Sasaki, N., Imanishi, M., Fujino, H., Tsuchiya, K., et al. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121590 · Cited by 32
Self-citationFerroptosis and renal fibrosis: mechanistic insights and emerging therapeutic targets
Lyu, G., Liao, H., & Li, R. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2498629 · Cited by 33
“…DFO inhibits ferroptosis by regulating iron metabolism, oxidative stress, and the tGF-β1/ Smad3 pathway, thereby alleviating renal fibrosis [90,118]. in the cKD model induced by 5/6 nephrectomy, DFX reduced renal interstitial fibrosis in cKD rats by inhibiting tGF-β, inflammation, and partial…”
Novel Insight into Ferroptosis in Kidney Diseases
Liu, Y., Liu, Y., Zhou, S., Feng, Q., Lu, Y., Liu, D., & Liu, Z. (2023) · American Journal of Nephrology · doi:10.1159/000530882 · Cited by 28
Iron and ferroptosis in kidney disease: molecular and metabolic mechanisms
Wang, W., Chen, J., Zhan, L., Zou, H., Wang, L., Guo, M., Gao, H., Xu, J., & Wu, W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1531577 · Cited by 41
Oshima, K., Ikeda, Y., Horinouchi, Y., Watanabe, H., Hamano, H., Kihira, Y., Kishi, S., Izawa‐Ishizawa, Y., Miyamoto, L., Hirayama, T., et al. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.11 · Cited by 25
Self-citationImmunoliposomes for Targeted Delivery of an Antifibrotic Drug
Schuster, L., Seifert, O., Vollmer, S., Kontermann, R. E., Schlosshauer, B., & Hartmann, H. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00012 · Cited by 25
The Effect of Angiotensin-(1-7) in Mouse Unilateral Ureteral Obstruction
Zimmerman, D. L., Zimpelmann, J., Xiao, F., Gutsol, A. A., Touyz, R. M., & Burns, K. D. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.11.013 · Cited by 22
Gronkiewicz, K. M., Giuliano, E. A., Sharma, A., & Mohan, R. R. (2015) · Veterinary Ophthalmology · doi:10.1111/vop.12331 · Cited by 23
Packer, M. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3238 · Cited by 21
Iron overload and mitochondrial dysfunction orchestrate pulmonary fibrosis
Li, S., Zhang, H., Chang, J., Li, D., & Cao, P. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174613 · Cited by 30
Tsai, L.-T., Weng, T., Chang, T.-Y., Lan, K., Chiang, C., & Liu, S. (2023) · Antioxidants · doi:10.3390/antiox12111931 · Cited by 18
“Previous studies have shown that DFO attenuates aortic calcification in rats with 5/6 nephrectomy-induced CKD [55] and prevents renal tubulointerstitial fibrosis in a unilateral ureteral obstruction (UUO)-CKD mouse model [56].”
BackgroundEvidence of Renal Iron Accumulation in a Male Mouse Model of Lupus
Theut, L. R., Dsouza, D. L., Grove, R. C., & Boesen, E. I. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00516 · Cited by 17
Alpha lipoic acid attenuates iron induced oxidative acute kidney injury in rats
Çavdar, Z., Oktan, M. A., Ural, C., Koçak, A., Çalışır, M., Heybeli, C., Yıldız, S., Özbal, S., Arslan, Ş., Ergür, B. U., et al. (2020) · Biotechnic & Histochemistry · doi:10.1080/10520295.2020.1812001 · Cited by 16
“Ikeda et al. (2014) also reported that expression of Nox4 and p22phox in the kidney was decreased by deferoxamine, which is an iron chelator, followed by decreased oxidative stress.”
BackgroundFerroptosis in renal fibrosis: a mini-review
Yang, S., Zhao, X., Zhang, J., Liao, D., Wang, Y., & Wang, Y.-G. (2024) · Journal of drug targeting · doi:10.1080/1061186x.2024.2353363 · Cited by 17
Preconditioning against renal ischaemia reperfusion injury: the failure to translate to the clinic
O'Kane, D. B., Baldwin, G. S., Bolton, D. M., Ischia, J. J., & Patel, O. (2019) · Journal of Nephrology · doi:10.1007/s40620-019-00582-6 · Cited by 16
Kidney tubule iron loading in experimental focal segmental glomerulosclerosis
van Swelm, R. P. L., Beurskens, S., Dijkman, H. B. P. M., Wiegerinck, E. T. G., Roelofs, R., Thévenod, F., van der Vlag, J., Wetzels, J. F. M., Swinkels, D. W., & Smeets, B. (2022) · Scientific Reports · doi:10.1038/s41598-022-05261-4 · Cited by 16
Hypoxia-Driven Responses in Chronic Kidney Disease
Miguel, V., & Rojo, A. (2023) · Oxygen · doi:10.3390/oxygen3030020 · Cited by 15
Mitochondrial dysfunction: the hidden catalyst in chronic kidney disease progression
Chen, J., Zhou, Q., Su, L., & Ni, L. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2506812 · Cited by 20
Erythropoiesis-independent effects of iron in chronic kidney disease
Patiño, E., & Akchurin, O. M. (2021) · Pediatric Nephrology · doi:10.1007/s00467-021-05191-9 · Cited by 13
Role of persistent necroinflammation in chronic tissue remodeling and organ fibrosis
More, S. A., Ghosh, A., Kulkarni, O. P., & Mulay, S. R. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00416.2025 · Cited by 12
Fakharzadeh, S., Argani, H., Torbati, P. M., Dadashzadeh, S., Kalanaky, S., Nazaran, M. H., & Basiri, A. (2020) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2020.126547 · Cited by 11
Affinity Effects on the Release of Non-Conventional Antifibrotics from Polymer Depots
Rohner, N. A., Nguyen, D. V., & von Recum, H. A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030275 · Cited by 9
“Deferoxamine (DFOA) Treating iron/aluminum toxicity SQ, IM, IV Decreases oxidative stress and necrosis [16] Enhances neovascularization [17] Reduces interstitial renal fibrosis [18]”
BackgroundMechanisms and therapeutic potential of multiple forms of programmed cell death in renal fibrosis
Chen, Y., Liu, F., Dai, R., Cheng, M., Wang, W., Sang, Y., Wei, L., Wang, Y., & Zhang, L. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111926 · Cited by 11
The main molecular mechanisms of ferroptosis and its role in chronic kidney disease
Wang, F., Huang, X., Wang, S., Wu, D., Zhang, M., & Wei, W. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111256 · Cited by 13
Yatmark, P., Morales, N. P., Chaisri, U., Wichaiyo, S., Hemstapat, R., Srichairatanakool, S., Svasti, S., & Fucharoen, S. (2016) · Experimental and Toxicologic Pathology · doi:10.1016/j.etp.2016.06.006 · Cited by 9
Pan, S., Qian, Z., Cui, S., Zhao, D., Lan, W., Wang, X., & Chen, X. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.11.066 · Cited by 8
COVID-19 as part of the hyperferritinemic syndromes: is there a role for iron depletion therapy?Preprint
Perricone, C., Bartoloni, E., Bursi, R., Cafaro, G., Guidelli, G. M., Shoenfeld, Y., & Gerli, R. (2020) · doi:10.22541/au.158880283.34604328 · Cited by 8
METTL3 / YTHDF3 m6A axis promotes ferroptosis in diabetic kidney disease by stabilizing TfR1
Zhang, J., Zhou, X., Wang, B., Yin, Y., Wei, D., & Li, K. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70094 · Cited by 7
“Various research indicates that the pathogenesis of ferroptosis involved in DKD includes renal tubule injury, mesangial cell injury, and renal fi brosis 15 – 17 .”
Unraveling Ferroptosis: A New Frontier in Combating Renal Fibrosis and CKD Progression
Jin, R., Dai, Y., Wang, Z., Hu, Q., Zhang, C., Gao, H., & Qi, Y. (2024) · Biology · doi:10.3390/biology14010012 · Cited by 11
Yokota, T., Omachi, K., Suico, M. A., Kojima, H., Kamura, M., Teramoto, K., Kaseda, S., Kuwazuru, J., Shuto, T., & Kai, H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183959 · Cited by 7
Chatterjee, T., & Zarjou, A. (2025) · Advances in Kidney Disease and Health · doi:10.1053/j.akdh.2024.12.004 · Cited by 7
Abe, E., Yamashita, A., Hirota, K., Yamaji, T., Azushima, K., Urate, S., Suzuki, T., Tanaka, S., Taguchi, S., Tsukamoto, S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-22343-5 · Cited by 6
Identification of ferroptosis‑associated genes in chronic kidney disease
Shao, L., Fang, Q., Ba, C., Zhang, Y., Chen, S., Zhang, Y., & Wang, J. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11759 · Cited by 7
“Accordingly, the use of ferroptosis‐inhibiting compounds, such as deferoxamine or ferrostatin‐1, can protect against intersti‐ tial fibrosis, renal damage and accumulation of inflammatory cells in IRI or UUO‐induced mice (7,49).”
BackgroundLv, S., Fan, L., Chen, X., Su, X., Dong, L., Wang, Q., Wang, Y., Zhang, H., Cui, H., Zhang, S., et al. (2024) · Journal of Diabetes Research · doi:10.1155/2024/9990304 · Cited by 8
Effects of iron chelating agent on Schistosoma mansoni infected murine model
Abdelgelil, N. H., Abdellatif, M. Z. M., Abdel-Hafeez, E. H., Belal, U. S., Mohamed, R. M., Abdel‐Razik, A. H., Hassanin, K. M. A., & Abdel‐Wahab, A. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.036 · Cited by 6
Systemic and local hepcidin as emerging and important peptides in renal homeostasis and pathology
Vela, D. (2018) · BioFactors · doi:10.1002/biof.1468 · Cited by 5
Improving Fat Graft Survival Using Soluble Molecule Preconditioning
Amraoui, N., Xu, I., Cortés, J. R., Cloutier, C. B., & Fradette, J. (2025) · Biomolecules · doi:10.3390/biom15040526 · Cited by 5
“This is in accordance with other studies showing that DFX may be able to decrease tissue fibrosis in renal tissue and irradiated wounds [74,75].”
Xu, Y., Huang, S., Zhou, S., Wang, X., Wei, M., Chen, X., Zong, R., Lin, X., Li, S., Liu, Z., et al. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.10.5 · Cited by 7
Fakharzadeh, S., Argani, H., Dadashzadeh, S., Kalanaky, S., Torbati, P. M., Nazaran, M. H., & Basiri, A. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s240757 · Cited by 6
Possible therapeutic impact of the iron chelation on renal fibrosis
Tamura, K., Uneda, K., Azushima, K., Wakui, H., & Haruhara, K. (2015) · Hypertension Research · doi:10.1038/hr.2015.60 · Cited by 4
Abe, E., Yamashita, A., Hirota, K., Yamaji, T., Azushima, K., Urate, S., Suzuki, T., Tanaka, S., Taguchi, S., Tsukamoto, S., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1830267/v1 · Cited by 4
Liu, K., Yu, M., He, Y., Wang, T., Li, G., Wang, L., & Zhong, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1610573 · Cited by 7
“…fi brosis by downregulating the TGF-β 1/SMAD3 signaling pathway, inhibiting the activation of fi broblasts, downregulating the expression of monocyte chemoattractant protein-1 (MCP-1), and inhibiting macrophage chemotaxis (Wang J. et al., 2022; Li et al., 2022; Ikeda et al., 2014; Lyu et al., 2025).”
Muhammad, M. H. (2017) · American Journal of Biomedical Sciences · doi:10.5099/aj170200062 · Cited by 3
Votava, J. A., Reese, S. R., Deck, K. M., Nizzi, C. P., Anderson, S. A., Djamali, A., & Eisenstein, R. S. (2021) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00537.2020 · Cited by 4
Kamiya, T., Nishimura, M., Otsuka, T., Yoshinaka, H., Maruyama, H., Kono, H., & Hara, H. (2025) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.25-42 · Cited by 2
“(32) In addition, it has been reported that ferrostatin-1 and liproxstatin-1 significantly suppress ferroptosis through the inhibition of lipid peroxidation.”
ATP-binding cassette B8 prevents endothelial dysfunction and atherosclerosis
Chaker, A. B., Rinaldi, L., Gillham, O., Pérez‐Ternero, C., Bosseboeuf, E., Dyson, N., Smith, D. S., Ardehali, H., Fantin, A., Chikh, A., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103903 · Cited by 2
“Furthermore, these data indicate that in ECs, TGF-β acts as an iron effector, similarly to epithelial cells in which iron induces TGF-β -mediated mitochondrial ROS, epithelial to mesenchymal transition and fibrosis [67 – 69].”
Katikaneni, D. S., Arekar, T., Al-Hraki, L., Garcia, G., Reedy, N., Morel, L. M., Manolova, V., & Scindia, Y. M. (2026) · Clinical Immunology · doi:10.1016/j.clim.2026.110699 · Cited by 2
Lake, J. L., Mariniello, M., Schiano, G., Guo, Q., Mabillard, H. R., Sayer, J. A., Olinger, E. G., Terzi, F., & Devuyst, O. (2026) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000001077 · Cited by 5
Scindia, Y. M. (2024) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00384.2023 · Cited by 2
Soong, T., Feng, I., Chen, J., Chen, I., Tong, H.-Y., Yang, M.-Y., Wu, S.-F., Yew, M. K., & Hung, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-01608-5 · Cited by 1
Zhu, Y., Liu, Y., Wang, H.-C., Geng, Z., Kan, Y., Cao, X., & Yan, X. (2025) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-025-03688-0 · Cited by 1
“Compensatory changes, including downregulation of TFR expression and upregulation of ferroportin (FPN) expression in proximal tubule cells, have also been observed in CKD animal models [11].”
PM2.5-induced ferroptosis via the miR-188-3p/GPX4 axis disrupts renal erythropoietin production
Chen, W., Chen, S., Bai, L., Zhang, M., Dong, C., Fan, L., Zan, Q., & Li, R. (2026) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2026.117774 · Cited by 1
Ding, X., Li, P., Tan, C., Wang, L., Liu, P., Zhou, X., Bai, Y., Guo, Y., & Zhang, C. (2022) · Journal of Radiation Research and Applied Sciences · doi:10.1016/j.jrras.2022.05.007
Discovery Pipeline for Acute Kidney Injury: Molecules, Mechanisms, Models, and Targets
Chatterjee, T., Rutkowski, J. M., Soranno, D. E., Goggins, E. S., Okusa, M. D., Prenna, S., Cantaluppi, V., & Zarjou, A. (2025) · The Nephron journals/Nephron journals · doi:10.1159/000549795
“Iron chelators, including deferoxamine, desferox, and ci-clopirox, confer protection in cisplatin-induced and obstructive nephropathy by reducing labile iron and limiting iron-driven oxidative stress [38, 39].”
Moon, D., & Kim, J. (2026) · Pharmacological Reports · doi:10.1007/s43440-026-00881-3
Yin, P., Chen, L., Ding, M., Wei, Z., Huo, A., Wang, Y., Xie, M., Zhang, H., Qin, Y., Ding, H., et al. (2026) · Cell Death and Differentiation · doi:10.1038/s41418-026-01868-6
Impact of renal iron overload on sickle cell nephropathy in a humanized mouse model
Sako, M. O., Kane, B. J., Booze, M., Walker, S., Patel, M., Swamigari, S., Nguyen, H., Hyndman, K. A., Mitchell, T., Bolisetty, S., et al. (2026) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00096.2026
Metadata
- Authors
- Ikeda, Y., Ozono, I., Tajima, S., Imao, M., Horinouchi, Y., Izawa-Ishizawa, Y., Kihira, Y., Miyamoto, L., Ishizawa, K., Tsuchiya, K., & Tamaki, T.
- Affiliations
- Tokushima University (JP)
- Corresponding author
- Ikeda, Yasumasa
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-02-19
- Volume
- 9
- Issue
- 2
- Pages
- e89355
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3929716
- OpenAlex
- W1977079786
- Cited by
- 98
- References
- 62
- Citations by year
- 2026: 6 · 2025: 14 · 2024: 10 · 2023: 7 · 2022: 11 · 2021: 7 · 2020: 9 · 2019: 10 · 2018: 6 · 2017: 6 · 2016: 4 · 2015: 7 · 2014: 1
- FWCI
- 4.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (publishedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Osaka Foundation for Promotion of Fundamental Medical Research
- Japan Society for the Promotion of Science (24790254, 24591203, 25860063)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- deferoxamine, iron chelation, tubulointerstitial fibrosis, unilateral ureteral obstruction, chronic kidney disease, TGF-β1/Smad3 signaling, oxidative stress, NADPH oxidase, macrophage infiltration, inflammation, extracellular matrix, iron metabolism, ferroportin, ferritin, transferrin receptor, DMT1
- MeSH terms
- Animals, Deferoxamine, Fibrosis, Immunohistochemistry, Iron Chelating Agents, Kidney Diseases, Ureteral Obstruction, Blotting, Western, Signal Transduction, Chelation Therapy, Transforming Growth Factor beta, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.